Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Abivax Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone August 06, 2024 From Abivax Via GlobeNewswire Tickers ABVX Abivax Provides Operational and Key Program Update July 15, 2024 From Abivax Via GlobeNewswire Tickers ABVX Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting June 04, 2024 From Abivax Via GlobeNewswire Tickers ABVX Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024 May 08, 2024 From Abivax Via GlobeNewswire Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents May 07, 2024 From Abivax Via GlobeNewswire Abivax publishes financial reports with the French and U.S. securities regulatory agencies April 05, 2024 From Abivax Via GlobeNewswire Abivax reports 2023 financial results and operational update April 02, 2024 From Abivax Via GlobeNewswire Abivax appoints Ana Sharma as Vice President, Global Head of Quality February 07, 2024 From Abivax Via GlobeNewswire Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease February 02, 2024 From Abivax Via GlobeNewswire Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024 January 24, 2024 From Abivax Via GlobeNewswire Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months January 22, 2024 From Abivax Via GlobeNewswire Abivax 2024 Financial Communication Calendar January 04, 2024 From Abivax Via GlobeNewswire Abivax announces the resumption of its liquidity contract November 21, 2023 From Abivax Via GlobeNewswire Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference November 14, 2023 From Abivax Via GlobeNewswire Abivax Releases the Results of its June 9, 2022 Ordinary Annual and Extraordinary General Meeting June 10, 2022 From ABIVAX Via AccessWire Abivax Phase 2a Study Results of Obefazimod (ABX464) in Rheumatoid Arthritis Published in the Journal "Annals of the Rheumatic Diseases" and Selected for Presentation at EULAR 2022 June 01, 2022 From ABIVAX Via AccessWire Abivax Announces Annual Ordinary and Extraordinary General Meeting on June 9, 2022, and the Availability of the Preparatory Documents May 18, 2022 From ABIVAX Via AccessWire Abivax Publishes Universal Registration Document 2022 'Document d'Enregistrement Universel' April 28, 2022 From ABIVAX Via AccessWire Abivax Reports Excellent One-Year Efficacy and Safety Data of ABX464 Phase 2b Maintenance Trial in Ulcerative Colitis April 06, 2022 From ABIVAX Via AccessWire Abivax Reports 2021 Financial Results and Operations Update March 16, 2022 From ABIVAX Via AccessWire Abivax Reports Promising ABX464 Phase 2a One-Year Maintenance Results in Rheumatoid Arthritis March 10, 2022 From ABIVAX Via AccessWire Abivax to host Satellite Symposium at the 17th Congress of ECCO on Feb. 17, 2022 February 08, 2022 From ABIVAX Via AccessWire Abivax 2022 Financial Communication Calendar January 25, 2022 From ABIVAX Via AccessWire Abivax's Phase 1/2 Clinical Study Results of ABX196 in Liver Cancer to be Presented on Jan. 21, at ASCO GI Cancers Symposium 2022 January 19, 2022 From ABIVAX Via AccessWire Abivax Receives EMA Scientific Advice Supportive of Moving ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis January 13, 2022 From ABIVAX Via AccessWire Exposures Product Safety Abivax to Present at the J.P. Morgan 40th Annual Healthcare Conference December 15, 2021 From ABIVAX Via AccessWire Exposures Product Safety Abivax Receives FDA Feedback with Guidance on Advancing ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis December 01, 2021 From ABIVAX Via AccessWire Exposures Product Safety Abivax's Phase 1/2 Clinical Study Results of ABX196 in Liver Cancer Show Good Tolerability and Promising Signals of Clinical Benefit and were Selected for Presentation at the ASCO GI Cancers Symposium 2022 November 30, 2021 From ABIVAX Via AccessWire ABIVAX: ABX464 shows excellent long-term efficacy data in Abivax's phase 2b maintenance Trial in ulcerative colitis October 18, 2021 From ABIVAX Via AccessWire Exposures Product Safety Abivax Late-Breaking Abstract Presentation and Live Industry Symposium at the UEG Week Virtual 2021 September 28, 2021 From ABIVAX Via AccessWire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.